PFS evaluation in patients with advanced, non-resectable, progressive GEP-NET treated using combine radioligand/PRRT and CAPTEM therapy

#3495

Introduction: Prospective, single-arm, open-label, case series study with assessment the efficacy and safety of combined radioligand therapy (RLT/PRRT) and CAPTEM in advanced, non-resectable progressive GEP-NET (NCT04194125).

Aim(s): Primary endpoint locally assessed RECIST 1.0 progression-free survival (PFS). Secondary goals evaluation of clinical and objective response rate (ORR), disease control rate (DCR), biochemical response (CgA, NSE), also safety (AEs).

Materials and methods: Patients had proven progressive pancreatic/midgut NET. Combine therapy PRRT (177Lu DOTATOC) and CAPTEM. Clinical follow-up after therapy at least 24 m. Disease status and treatment efficiency were evaluated by clinical assessment including PS, ORR, also biochemical response and safety profile of combine therapy.

Conference:

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Nowicka G, Pałucki J,

Keywords: neuroendocrine tumor, combine therapy PRRT and CAPTEM, PFS,